Sussex Kidney Unit, Royal Sussex County Hospital, Brighton, UK.
Research and Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russian Federation.
Nephrol Dial Transplant. 2019 Mar 1;34(3):502-508. doi: 10.1093/ndt/gfy063.
Renal angiomyolipoma occurs at a high frequency in patients with tuberous sclerosis complex (TSC) and is associated with potentially life-threatening complications. Despite this frequency and severity, there are no large population-based cohort studies. Here we present baseline and follow-up data of the international TuberOus SClerosis registry to increase disease Awareness (TOSCA) with an aim to provide detailed clinical characteristics of renal angiomyolipoma among patients with TSC.
Patients of any age with a documented clinic visit for TSC within 12 months or who were newly diagnosed with TSC before participation in the registry were eligible. Data specific to renal angiomyolipoma included physical tumour characteristics (multiple, bilateral, lesion size and growing lesions), clinical signs and symptoms, and management. The effects of age, gender and genotype on the prevalence of renal angiomyolipoma were also evaluated.
Renal angiomyolipoma was reported in 51.8% of patients at baseline, with higher frequency in female patients (57.8% versus 42.2%). The median age at diagnosis was 12 years. Prevalence of angiomyolipoma was higher in patients with TSC2 compared with TSC1 mutations (59.2% versus 33.3%, P < 0.01). Of the 1031 patients with angiomyolipoma at baseline, multiple lesions were reported in 88.4% and bilateral in 83.9% of patients, while the size of angiomyolipoma was >3 cm in 34.3% of patients. Most patients were asymptomatic (82%). Frequently reported angiomyolipoma-related symptoms included bleeding, pain, elevated blood pressure and impaired renal function. Embolization and mammalian target of rapamycin inhibitors were the two most common treatment modalities.
The TOSCA registry highlights the burden of renal angiomyolipoma in patients with TSC and shows that renal manifestations are initially asymptomatic and are influenced by gender and genotype. Furthermore, the occurrence of significant problems from angiomyolipoma in a minority of younger patients suggests that surveillance should begin in infancy or at initial diagnosis.
在结节性硬化症(TSC)患者中,肾血管平滑肌脂肪瘤(angiomyolipoma,AML)的发生率较高,并且与潜在的危及生命的并发症相关。尽管其发生率和严重程度如此之高,但目前尚无大型基于人群的队列研究。在此,我们展示了国际结节性硬化症登记处(TOSCA)的基线和随访数据,旨在提高对 TSC 患者肾血管平滑肌脂肪瘤的疾病认识,并提供此类患者的详细临床特征。
在登记前 12 个月内有记录的 TSC 临床就诊或新诊断为 TSC 的任何年龄的患者均符合条件。与肾血管平滑肌脂肪瘤相关的数据包括实体瘤特征(多发性、双侧、病变大小和生长病变)、临床症状和管理。还评估了年龄、性别和基因型对肾血管平滑肌脂肪瘤发生率的影响。
基线时报告了 51.8%的患者患有肾血管平滑肌脂肪瘤,女性患者的频率更高(57.8%比 42.2%)。中位诊断年龄为 12 岁。与 TSC1 突变相比,TSC2 突变患者的血管平滑肌脂肪瘤发生率更高(59.2%比 33.3%,P<0.01)。在基线时有血管平滑肌脂肪瘤的 1031 名患者中,88.4%的患者有多个病变,83.9%的患者有双侧病变,而 34.3%的患者的血管平滑肌脂肪瘤大小>3cm。大多数患者无症状(82%)。常报告的血管平滑肌脂肪瘤相关症状包括出血、疼痛、血压升高和肾功能受损。栓塞和哺乳动物雷帕霉素靶蛋白抑制剂是两种最常见的治疗方式。
TOSCA 登记处强调了 TSC 患者肾血管平滑肌脂肪瘤的负担,并表明肾表现最初是无症状的,且受性别和基因型的影响。此外,少数年轻患者的血管平滑肌脂肪瘤出现严重问题表明,应在婴儿期或初始诊断时开始进行监测。